Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 1Lymphoid 1

Conditions

Primary Myelofibrosis 4Myeloproliferative Disorders 4Carcinoma, Non-Small-Cell Lung 4Hematologic Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Hodgkin Disease 2Thrombocytosis 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Inhibition, Psychological 1Histiocytoma, Malignant Fibrous 1Hematologic Diseases 1

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Cyclosporins 14Biopsy 14Alemtuzumab 14thymoglobulin 13venetoclax 11sargramostim 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Myeloproliferative Disorders × INCB039110 × Clear all
NCT05364762 2026-06-03

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

City of Hope Medical Center

Phase 2 Active not recruiting
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Incyte Corporation

Phase 2 Completed
4 enrolled 10 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Incyte Corporation

Phase 2 Completed
23 enrolled 31 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01633372 2021-08-30

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Incyte Corporation

Phase 2 Completed
87 enrolled
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡